During the corresponding time, 20/20 Biolabs, Inc. saw a revenue deteriorated by -36.19 % year on year, While revenue at the 20/20 Biolabs, Inc.'s corporate clients
20/20 Biolabs's Comment on Sales, Marketing and Customers
The company serves customers such as fire departments reimbursed by state funding for MCED tests, including its proteomic-based OneTest for Cancer. Its market includes scientists, clinicians, and self-insured employers who use or develop ctDNA-based tests. OneTest for Cancer is positioned as a more affordable and earlier-stage detection alternative. Available in the U.S. for under $200, OneTest can be administered at home without needles and was validated by the National Cancer Institute in 2024. The company offers OneTest Standard and OneTest Premium, with the latter representing more than two-thirds of all OneTest customers. OneTest Premium, exclusively licensed from BioInfra Life Science, Inc., targets detection of eight specific tumor types, while OneTest Standard provides a pan-cancer likelihood score. Customers and markets referenced include BioInfra Life Science, Inc., Grail, and the National Cancer Institute.
20/20 Biolabs’s Comment on Sales, Marketing and Customers
The company serves customers such as fire departments reimbursed by state funding for MCED tests, including its proteomic-based OneTest for Cancer. Its market includes scientists, clinicians, and self-insured employers who use or develop ctDNA-based tests. OneTest for Cancer is positioned as a more affordable and earlier-stage detection alternative. Available in the U.S. for under $200, OneTest can be administered at home without needles and was validated by the National Cancer Institute in 2024. The company offers OneTest Standard and OneTest Premium, with the latter representing more than two-thirds of all OneTest customers. OneTest Premium, exclusively licensed from BioInfra Life Science, Inc., targets detection of eight specific tumor types, while OneTest Standard provides a pan-cancer likelihood score. Customers and markets referenced include BioInfra Life Science, Inc., Grail, and the National Cancer Institute.
Sources:
20/20 Biolabs, Inc.’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: 20/20 Biolabs, Inc.’s corporate clients.
For your research, we’ve provided 9 tables on 20/20 Biolabs, Inc. corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
3.01 %